### Highlights of This Issue 2823

#### REVIEW

2825 Mechanisms of Resistance to Antibody–Drug Conjugates  
Frank Loganzo, Matthew Sung, and Hans-Peter Gerber

#### SMALL MOLECULE THERAPEUTICS

2835 Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth  
Jun Chen, Taisei Kinoshita, Juthamas Sukbuntheng, Betty Y. Chang, and Laurence Elias

2845 Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations  
Yemarschet K. Gebreyohannes, Patrick Schoffski, Thomas Van Looy, Jasmien Wellens, Lise Vreys, Jasmien Cormillie, Ulla Vanleeuw, Dana T. Aftab, Maria Debiec-Rychter, Raf Sciot, and Agnieszka Wozniak

2853 Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts  
Jerec W. Ricci, Debbie M. Lovato, Virginia Severns, Larry A. Sklar, and Richard S. Larson

2863 Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells  
Eeman Mukhtar, Vaqar Mustafa Adhami, Imtiaz Ahmad Siddiqui, Ajit Kumar Verma, and Hasan Mukhtar

2875 Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer  
Stepana Boukalova, Jan Stursa, Lukas Werner, Zuzana Ezrova, Jiri Cerny, Ayenachew Bezawork-Geleta, Alena Pecinova, Lanfeng Dong, Zdenek Drahota, and Jiri Neuzil

2887 Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer  
Jianfeng Lu, Donna McEachern, Shunqiang Li, Matthew J. Ellis, and Shaomeng Wang

#### LARGE MOLECULE THERAPEUTICS

2905 Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells  
Sagar Uttarkar, Therese Piontek, Sandeep Dukaure, Caroline Schomburg, Peter Schlenke, Wolfgang E. Berdel, Carsten Muller-Tidow, Thomas J. Schmidt, and Karl-Heinz Klenpmauer

2916 CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation  
Dan-Dan Wang, Ying Chen, Zi-Bo Chen, Fang-Jie Yan, Xiao-Yang Yang, Mei-Dan Ying, Ji Cao, Jian Ma, Pei-Hua Luo, Yong-Xin Han, Yong Peng, Ying-Hui Sun, Hui Zhang, Qiao-Jun He, Bo Yang, and Hong Zhu

2926 Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma  
Samuele Cazzamalli, Alberto Dal Corso, and Dario Neri

2936 Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation  

2946 Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1  

### December 2016 • Volume 15 • Number 12
Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na⁺/K⁺-ATPase Signalsome
Miao Liu, Li-Xing Feng, Peng Sun, Wang Liu, Tian Mi, Min Lei, Wanying Wu, Baosheng Jiang, Min Yang, Libong Hu, De-An Guo, and Xuan Liu

Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Xiaoyun Dai, Kwang Seok Ahn, Ling Zhi Wang, Chulwon Kim, Anudha Deviasigammi, Frank Arfuso, Jae-Young Um, Alan Prem Kumar, Young-Chae Chang, Dhiraj Kumar, Gopal C. Kundu, Jonji Magsanoc, Boon Cher Goh, Kam Man Hui, and Gautam Sethi

The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development
Shuang Liu, Ramkrishna Mitra, Ming-Ming Zhao, Wenhong Fan, Christine M. Eischen, Feng Yin, and Zhongming Zhao

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells
Teresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, Harold G. Parkes, Richard Marais, Paul Workman, Martin O. Leach, and Mounia Beloueche-Babari

Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Alfeu Zanotto-Filho, V. Pragathi Masamsetti, Eva Loranc, Sonal S. Tonapi, Aparna Gorthi, Xavier Bernard, Ros Angela Mayer Goncalves, Jocelyn C.F. Moreira, Yidong Chen, and Alexander J.R. Bishop

Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance That Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer
Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Shamit K. Dutta, Debabrata Mukhopadhyay, and Frank A. Sinicrope

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
Timothy A. Marlowe, Felicia L. Lenzo, Sheila A. Figel, Abigail T. Grapes, and William G. Cance

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Toshimitsu Yamaoka, Tohru Ohnori, Motoi Ohba, Satoru Arata, Yasunari Kishino, Yasunori Murata, Sojuro Kusuomoto, Hiroo Ishida, Takao Shirai, Takashi Hirose, Tsukasa Ohsnishi, and Yasutsuna Sasaki

STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A
Shao Wang, Cedric Darini, Laurent Desaubry, and Antonis E. Koromilas

Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model
Gina Lee, Brenda Aufinger, Donna Guo, Tanvir Hasan, Marc Deheeger, Alex L. Tobias, Jeong Yeon Kim, Fatemeh Atashi, Lingjiiao Zhang, Maciej S. Lesniak, C. David James, and Atique U. Ahmed

Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Leon P. Pradel, Chia-Huey Ooi, Solange Romagnoli, Michael A. Cannarile, Hadasah Sade, Dominik Rüttiger, and Carola H. Ries

ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis
Vinod Vijay Subhash, Shi Hui Tan, Mei Shi Yeo, Fu Leng Yan, Praveen C. Peethala, Natalia Liem, Vaidehi Krishnan, and Wei Peng Yong

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Nicole Willemsen-Seegers, Judith R.F. de Vetere, Jelle Dylus, Antoon M. van Doornmalen, Jeffrey Kooijman, Massaki Sawa, Suzanne J.C. van Gerwen, Jos de Man, Rogier C. Buijsman, and Guido J.R. Zaman

Downloaded from mct.aacrjournals.org on September 1, 2021. © 2016 American Association for Cancer Research.
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Miro J. Eigenmann, Nicolas Frances, Gerhard Hoffmann, Thierry Lavé, and Antje-Christine Walz

Correction: Antagonists of IGF: Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions

Acknowledgment to Reviewers
Molecular Cancer Therapeutics

15 (12)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/15/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/15/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.